Literature DB >> 9367026

Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas.

W J Temple1, C L Temple, K Arthur, N S Schachar, A H Paterson, T S Crabtree.   

Abstract

BACKGROUND: 1994 marked a decade since the inception of a prospective population-based study on the value of neoadjuvant approach for soft tissue sarcomas of head, neck, and limbs at the Tom Baker Cancer Centre, Calgary, Alberta. To date, 42 patients have been followed for a minimum of 5 years or until death.
METHODS: Each patient received a protocol of 60 mg to 90 mg of Adriamycin infused intra-arterially or intravenously over 3 days into a vessel feeding the involved area, 30 Gy of radiotherapy given over 10 days, and complete resection of the sarcoma 4 to 6 weeks later. The lower dose was used empirically for smaller limbs (e.g., arm).
RESULTS: Two of the 42 patients were immediate failures of protocol, with one requiring amputation and one requiring later reexcision. In the 38 appendicular lesions, the ultimate limb salvage rate was 97.5%. All tumors were associated with a high risk of local recurrence with 15 being previous local failures. The rest were deep and grade 2 or 3 lesions. Serious local complications were seen in one patient (2.5%) who had wound necrosis requiring reoperation. Minor wound complications were seen in five patients (12.5%) (one wound infection, one resolved edema, three long-term drainage). There was one local recurrence; thus 5-year local control was 97%. No patient had long-term morbidity related to the treatment. No effect on systemic control was suggested.
CONCLUSION: Our report demonstrates that this combined modality approach provides superior local control of soft tissue sarcomas with low postoperative morbidity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367026     DOI: 10.1007/bf02305541

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies.

Authors:  Rick L M Haas; Aisha B Miah; Cécile LePechoux; Thomas F DeLaney; Elizabeth H Baldini; Kaled Alektiar; Brian O'Sullivan
Journal:  Radiother Oncol       Date:  2015-12-21       Impact factor: 6.280

Review 2.  Preoperative Radiation for Soft Tissue Sarcomas: How Much Is Needed?

Authors:  Safia K Ahmed; Ivy A Petersen
Journal:  Curr Treat Options Oncol       Date:  2022-02-15

3.  Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma.

Authors:  Meena Bedi; Reena Singh; John A Charlson; Tracy Kelly; Candice Johnstone; Adam Wooldridge; Donald A Hackbarth; Nicole Moore; John C Neilson; David M King
Journal:  Adv Radiat Oncol       Date:  2022-01-25

4.  Multimodality therapy for metastatic sarcomas confined to the lung.

Authors:  Russell P Gollard; J Francis Turner
Journal:  Oncol Lett       Date:  2012-07-24       Impact factor: 2.967

Review 5.  Neoadjuvant Treatment Options in Soft Tissue Sarcomas.

Authors:  Mateusz Jacek Spałek; Katarzyna Kozak; Anna Małgorzata Czarnecka; Ewa Bartnik; Aneta Borkowska; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

6.  (Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series.

Authors:  Riikka Nevala; Erkki Tukiainen; Maija Tarkkanen; Tom Böhling; Carl Blomqvist; Mika Sampo
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

Review 7.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.